Adjuvant immunotherapy reduces relapse risk in resected or ablated hepatocellular cancer
Data from the IMbrave050 study show benefits of atezolizumab plus bevacizumab in terms of disease recurrence, but long-term data are needed
Aspirin in colorectal cancer – has it still a place in secondary prevention?
Negative results from the ASCOT trial should not discourage researchers from investigating the drug’s potential in some molecularly distinct subgroups
Studies confirm the promise of ctDNA for MRD assessment in colorectal cancer, but limitations remain
Despite positive results from trials, the use of different assays with variable sensitivities and specificities impact their interpretation and clinical validation
Neoadjuvant nivolumab plus relatlimab shows benefit in MMR-deficient colon cancers
In the NICHE-3 study, all patients achieved a pathological response
Advanced pancreatic cancer: is triple chemotherapy into question?
Results presented at ESMO Congress 2023 open-up an interesting debate on the use of currently recommended treatment regimens
Triplet therapy does not outperform doublet treatment first line in metastatic pancreatic cancer
Results from the JCOG1611-GENERATE trial fuel the debate around the preferred option in this setting
New treatment paradigms may offer advances in pancreatic cancer treatments
Neoadjuvant, perioperative, targeted and combined treatment approaches have shown potential benefit for patients with this aggressive disease, but further research is needed
Are we over-treating patients with locally advanced rectal cancer?
Recently presented results suggest that a subset of patients with early stage rectal cancer could skip pre-operative radiotherapy, thus raising some questions about the standard of care